PedAM
Pediatric Disease Annotations & Medicines
| Disease | rheumatoid arthritis |
| Phenotype | |vascular disease |
| Sentences | 69 |
| PubMedID- 21905005 | Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events. |
| PubMedID- 23749610 | Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. |
| PubMedID- 22337612 | Apolipoprotein b-containing lipoprotein subclasses as risk factors for cardiovascular disease in patients with rheumatoid arthritis. |
| PubMedID- 21411091 | Prediction of genetic risk for cardiovascular disease in patients with rheumatoid arthritis: present and promises. |
| PubMedID- 25011482 | Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis. |
| PubMedID- 25026799 | [cardiovascular diseases in patients with rheumatoid arthritis during long-term methotrexate therapy]. |
| PubMedID- 24268008 | Cardiovascular disease in rheumatoid arthritis. |
| PubMedID- 20842919 | [cardiovascular diseases in rheumatoid arthritis]. |
| PubMedID- 26180748 | The association of rheumatoid arthritis (ra) with increased vascular disease is well established (kitas et al. |
| PubMedID- 21420089 | Tnfa -308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. |
| PubMedID- 20040642 | Risk factors for cardiovascular disease in rheumatoid arthritis: defining treatment thresholds. |
| PubMedID- 24795506 | Lack of association between abo, ppap2b, adamst7, pik3cg, and ednra and carotid intima-media thickness, carotid plaques, and cardiovascular disease in patients with rheumatoid arthritis. |
| PubMedID- 22249350 | Risk factors for cardiovascular disease in rheumatoid arthritis. |
| PubMedID- 21388351 | Vascular endothelial growth factor a and cardiovascular disease in rheumatoid arthritis patients. |
| PubMedID- 23300117 | Objectives: to assess the effect of golimumab, with or without methotrexate (mtx), on serum lipids and inflammatory markers of cardiovascular disease (cvd) in patients with rheumatoid arthritis (ra) in two phase 3, randomised, placebo-controlled trials (go-before and go-forward). |
| PubMedID- 21276397 | [excess mortality from cardiovascular disease in patients with rheumatoid arthritis]. |
| PubMedID- 25969671 | Several epidemiological studies reported increased morbidity and mortality from cardiovascular diseases in patients with rheumatoid arthritis [2], and strong evidences from basic research and epidemiological studies support that inflammation and venous thrombosis are associated processes [3]. |
| PubMedID- 20827876 | Cardiovascular disease in rheumatoid arthritis: disease and treatment interactions and their implications on treatment decisions. |
| PubMedID- 26117596 | Prevention of cardiovascular disease in rheumatoid arthritis. |
Page: 1 2